Since the expansion of the war in Ukraine in February 2022, more than 14 million people have been internally displaced or forced to flee to neighboring countries as refugees, often losing access to health care. HIV and TB prevention and diagnosis services have been disrupted, and many people with HIV and TB have been forced to interrupt their lifesaving treatment. The war has left hundreds of thousands of people without electricity or water supplies, and almost half of the population is in need of humanitarian assistance.

In our newly released Partnership Report, we highlight how the Global Fund and Unitaid collaborate to accelerate equitable access to lifesaving health products that prevent, detect and treat HIV, TB and malaria. By combining Unitaid’s investments in innovative new health products with the Global Fund’s proven ability to take those tools to scale around the world, we increase return on investment, save more lives and reach the health-related Sustainable Development Goals more quickly.

BERLIN, 16 October 2023– Siemens Healthineers and the Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund), announced a partnership at the World Health Summit today to accelerate the use of artificial intelligence (AI) in X-ray screening for tuberculosis (TB), a preventable, treatable, and curable infectious disease that is again on the rise globally.

Global Fund, Stop TB Partnership and USAID announce new collaboration with Danaher to reduce price and increase access to Cepheid’s TB test. Five million additional tests can be procured with this lower price.

Results in the fight against HIV, TB and malaria exceed pre-COVID-19 numbers; yet colliding crises keep the world way off track to achieve 2030 targets.

GENEVA/WASHINGTON, 09 March 2023 – The Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund), the United States Agency for International Development (USAID) and the Stop TB Partnership announced a new collaboration today with Molbio Diagnostics that significantly reduces the price of the Truenat® MTB and MTB Plus tests, including a supply of MTB-RIF Dx tests for subsequent testing for rifampicin resistance, and ensures timely service and maintenance of diagnostic instruments. This collaboration will expand equitable access to quality rapid testing to underserved populations across all countries supported by the Global Fund, USAID and the Stop TB Partnership.

NEW YORK / GENEVA, 21 September 2022 – The United States of America-hosted pledging conference for the Global Fund to Fight AIDS, Tuberculosis and Malaria raised more than US$14.25 billion so far for the partnership’s work over the next three years. The conference in the margins of the UN General Assembly brought together more than 45 countries (including 18 Heads of State and Government), multilateral partners, private sector companies and civil society and community organizations. This support aims to save 20 million lives, avert 450 million new infections, and bring new hope for ending AIDS, TB and malaria. This investment will also strengthen health and community systems to leave no one behind and be resilient to future shocks.

GENEVA, 12 September 2022 – The Global Fund’s 2022 Results Report released today finds a significant rebound in 2021 for programs working to defeat HIV, tuberculosis (TB) and malaria. In 2020, the COVID-19 pandemic had a devastating impact on the fight against the three diseases, leading to the decline of key programmatic results across the three diseases for the first time in the history of the Global Fund. When the pandemic hit countries where the Global Fund works, the partnership rapidly mounted a response to deliver additional resources. This year, the new report shows those investments paid off and recovery is underway.

MONTREAL, 31 July 2022 – A new report [ download in English | Español | Français | Русский ] released by the Global Fund today at the 24th International AIDS Conference unveils key findings of the activities supported by the Global Fund’s Breaking Down Barriers initiative, a groundbreaking program launched in 2017 to provide intensive financial and technical support to 20 countries* to address stigma and discrimination, criminalization and other human rights-related obstacles that continue to threaten progress against HIV, tuberculosis (TB), and malaria.

-- Almost half of the world’s population has no or limited access to diagnostics

-- This situation is especially acute in low- and middle-income countries (LMICs) where diagnostics plays a critical role for treating and containing the spread of infectious diseases such as Tuberculosis (TB) and HIV

-- New partnership between Roche and the Global Fund supports low- and middle-income countries in broadening access to diagnostics, helping millions of previously undiagnosed people with TB and HIV get diagnosed and eventually treated